BerGenBio reports third quarter 2022 financial results and provides business update
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients - - Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations - - Strengthened financial position with support from largest shareholder - BERGEN, Norway, November 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “The recent